Allison Chan

National University of Singapore
Country flagSingapore

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Year:

2026

This commentary explores the concept and utility of studying oncogene co-expression at single-cell resolution and its clinical and biological implications. We emphasize the importance of scalable methods, mathematically driven quantification models, and artificial intelligence integration to enhance the clinical utility of this approach.

Year:

2025

Mechanisms for resistance to cytotoxic cancer drugs are dependent on dynamic changes in the biochemistry of cellular pathways, information which is hard to obtain at the systems level. Here we use a deep functional proteomics implementation of the Cellular Thermal Shift Assay to reveal a range of induced biochemical responses to gemcitabine in resistant and sensitive diffuse large B cell lymphoma cell lines. Initial responses in both, gemcitabine resistant and sensitive cells, reflect known targeted effects by gemcitabine on ribonucleotide reductase and DNA damage responses. However, later responses diverge dramatically where sensitive cells show induction of characteristic CETSA signals for early apoptosis, while resistant cells reveal biochemical modulations reflecting transition through a distinct DNA-damage signaling state, including opening of cell cycle checkpoints and induction of translesion DNA synthesis programs, allowing bypass of damaged DNA-adducts. The results also show the induction of a protein ensemble, labeled the Auxiliary DNA Damage Repair, likely supporting DNA replication at damaged sites that can be attenuated in resistant cells by an ATR inhibitor, thus re-establishing gemcitabine sensitivity and demonstrating ATR as a key signaling node of this response.

Year:

2025

Year:

2025

The DNA damage response (DDR) is a central regulator of cancer cell fate, coordinating both pro-death and pro-survival pathways in response to genotoxic stress. Here, we reveal an unexpected role for the DDR at the cell surface, in mediating immune evasion from complement-dependent cytotoxicity (CDC), an innate immune mechanism exploited by therapeutic monoclonal antibodies (mAbs). In the context of diffuse large B-cell lymphoma (DLBCL), where the anti-CD20 mAb rituximab utilizes CDC, we show that genotoxic chemotherapy induces expression of membrane-bound complement regulatory proteins (mCRPs) CD46, CD55, and CD59, thereby reducing CDC sensitivity and compromising rituximab activity. In this setting, CD59 emerged as the dominant DDR-induced inhibitor of complement-mediated killing. A high-throughput kinase inhibitor screen identified checkpoint kinase 1 (Chk1) as a critical mediator of this response. Mechanistically, DNA damage activates Chk1, enhancing CD59 transcription via an Sp1-bound promoter. Co-immunoprecipitation mass spectrometry revealed a Chk1 dependent remodelling of Sp1-associated complexes to a transcriptionally active state with recruitment of the histone acetyltransferase KAT2A. These findings expand the role of the DDR in immune resistance at the tumor cell surface, and highlight a negative interaction between chemotherapy and monoclonal antibodies that may require sequential administration or targeting of the Chk1– Sp1–CD59 axis. Significance The DNA Damage Response upregulates complement-protective proteins, extending its role in modulating immune evasion at the cell surface, with direct implications for combinations of chemotherapy and monoclonal antibodies widely used in cancer.

Year:

2025

Year:

2022

Year:

2021

Collaborators (14)

Joseph J Zhao

National University of Singapore

SINGAPORE
View details

Wai Leong Tam

Associate Professor (Adjunct)

National University Singapore Yong Loo Lin School of Medicine

SINGAPORE
View details

Heike I Grabsch

Professor

University of Leeds

UNITED KINGDOM
View details

Claudio Tripodo

-

ITALY
View details

Nurulhuda Mustafa

National University of Singapore

SINGAPORE
View details

Anand D. Jeyasekharan

National University of Singapore (NUS)

SINGAPORE
View details

Haoran Ma

National University of Singapore

SINGAPORE
View details

Leandro Cerchietti

Professor

NYU Langone Health

UNITED STATES
View details

Mark Cragg

Prof. at Faculty of Engineering and Physical Sciences

University of Southampton

UNITED KINGDOM
View details

Marco Foiani

Director

-

ITALY
View details

Ying Yu Liang

Senior Scientist

Agency for Science, Technology and Research (A*STAR)

SINGAPORE
View details

Supriya Srivastava

Senior Research Fellow

National University Singapore Yong Loo Lin School of Medicine

SINGAPORE
View details

Wee Joo Chng

National University of Singapore (NUS)

SINGAPORE
View details

Stefano Casola

Docenti

University of Milan

ITALY
View details